MRUS Merus BV

Major shareholder A/S Genmab recently acquired 2,978 shares of Merus (NASDAQ:MRUS) stock for approximately $288,866, increasing its total direct ownership to over 72.8 million shares. This purchase is part of a series of acquisitions by A/S Genmab between December 16th and 29th, totaling around 2.4 million shares at an average price of $97 each. The stock experienced a 7.1% decline to $90 following news of Merus confirming the completion of Genmab's acquisition and its intent to delist from Nasdaq.

Merus N.V. shares were halted after Nasdaq confirmed the final merger step of Genmab's $97-a-share cash acquisition closed, leading to the stock's delisting on December 31, 2025. Remaining shareholders will receive $97 per share in cash, though a portion will be withheld for Dutch dividend taxes. Genmab expects the acquisition to strategically advance its pipeline, notably with the addition of the late-stage head and neck cancer asset, petosemtamab.

Merus N.V. (MRUS) has announced its intention to delist its common shares from Nasdaq and deregister under Section 12(b) following back-end transactions. The company plans to file a Form 15 to suspend SEC reporting after the Form 25 becomes effective. Trading of Merus shares on Nasdaq ceased prior to the market open on December 30, 2025.

A/S Genmab acquired 561,042 shares of Merus (NASDAQ:MRUS) for $54.42 million on December 23rd, increasing its direct ownership to 72,589,817 shares, valued at approximately $7.04 billion. This latest transaction is part of a series of purchases by A/S Genmab in December, totaling over 1.36 million shares at $97.00 each. Merus currently trades at $90, with a market capitalization of $6.83 billion, and holds a consensus analyst rating of "Hold" with a price target of $93.56.

Merus N.V. (NASDAQ:MRUS) experienced a significant 48.0% decrease in short interest in December, reducing the total to 817,936 shares, representing 1.1% of shares sold short with a short-interest ratio of 0.6 days. Insider activity includes VP Harry Shuman selling shares for $796k, while major shareholder A/S Genmab purchased shares worth $20.6M. The stock is currently trading near its 52-week high, with a market cap of $7.35 billion, and holds a consensus "Hold" rating from analysts.

Stock traders executed an unusually high volume of call options for Merus (NASDAQ:MRUS) on Friday, with 52,417 contracts traded, representing a 3,555% increase over the typical daily volume. This surge in options activity indicates strong bullish sentiment for the biotechnology company. The article also highlights a significant insider purchase by A/S Genmab and provides an overview of Merus's stock performance, institutional ownership, and recent analyst ratings.